Browse studies

Find your next paid study

61 recruiting studies matching your filters

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic L…

Systemic Lupus Erythematosus

Estimated

~$10 – $7,500

AstraZenecaNCT05835310

Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinic…

Systemic Lupus Erythematosus

Estimated

~$10 – $8,750

UCB Biopharma SRLNCT06617325

Phase 3

A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously c…

Systemic Lupus Erythematosus

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06133972

Phase 3

ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment a…

Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

Estimated

~$10 – $7,500

AstraZenecaNCT07691970

Phase 2

Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps peopl…

Systemic Lupus Erythematosus

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07409181

Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Background: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cycl…

Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)

Estimated

~$10 – $675

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT05567198

Phase 3

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once…

Systemic Lupus Erythematosus

Estimated

~$10 – $7,500

AstraZenecaNCT07430306

Phase 1

A Phase 1, First-in-Human, Single Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of ABBV-519 in Subjects With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inf…

Systemic Lupus ErythematosusRheumatoid Arthritis

A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]

The purpose of this study is to evaluate the long-term safety and efficacy of orally administered enpatoran in participants with cutaneous manifestations of lu…

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

Estimated

~$10 – $8,750

EMD Serono Research & Development Institute, Inc.NCT07840287

Phase 1

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), incl…

SLESystemic Lupus Erythematosus (SLE)CAR T Cell+4 more

Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT06839976

Phase 1

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabo…

Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03816345

Phase 1

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to p…

Rheumatoid ArthritisSystemic Lupus Erythematosus

Estimated

~$10 – $7,500

AstraZenecaNCT07201558